CROs offering Immunogenicity Assays (ADA / NAb) with Antibody-Drug Conjugate (ADC)
11 published
11 published CROs match Immunogenicity Assays (ADA / NAb) and Antibody-Drug Conjugate (ADC).
Locations in this set include United States, China, United Kingdom, Australia, France, and India.
Capabilities that show up most often in this set: Biomarker Assays, Bioanalysis, Discovery Research, Flow Cytometry Services, and GLP Toxicology.
Matching companies
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
BioDuro-SundiaBioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.
CelerionGlobal CRO specializing in early-phase clinical research and bioanalytical sciences with 650+ beds across 30 countries and 50+ years of experience.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
Frontage LaboratoriesGlobal pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
KCAS BioLeading bioanalytical CRO with 45+ years of experience, supporting 315+ approved drugs through bioanalysis, biomarker, immunogenicity, flow cytometry, and clinical kitting services across US, EU, and Australia facilities.
Oncodesign ServicesContract research organization specializing in drug discovery and preclinical services for oncology, inflammation, and infectious diseases since 1995.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Reaction BiologyGlobal preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/immunogenicity-assays/antibody-drug-conjugate.md